Servier and Allogene Therapeutics Announce Data Presentations of UCART19 First-in-Human Trials at 60th American Society of Hematology (ASH) Annual Meeting

12/11/2018

Paris, France and South San Francisco, US, November 12, 2018 – Servier, an independent international pharmaceutical company, and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity with UCART19, the allogeneic anti-CD19 CAR T-cell product being developed by Servier and Allogene Therapeutics, will be presented during the 60th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 1-4 at the San Diego Convention Center.

 

UCART19 is under Servier-Sponsored early clinical development in the treatment of pediatric and adult relapsed/refractory acute lymphoblastic leukemia (ALL).

The ASH abstract is now available at www.hematology.org. The oral presentation will include additional data not available in the abstract. Details are as follows.

 

Session: 612. Acute Lymphoblastic Leukemia: Clinical

Abstract #896

Title: Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Presenter: Reuben Benjamin, MBBS, MRCP, FRCPath, Ph.D., King’s College Hospital, London

Session Date & Time: Monday, December 3, 4:30-6:00 p.m. PT

Presentation time: 4:45 p.m. PT

Location: Room 6A

 


About UCART19

UCART19 is an allogeneic CAR T-cell product candidate being developed for treatment of CD19-expressing hematological malignancies, gene edited with TALEN®, a gene-editing technology pioneered and owned by Cellectis. UCART19 is being developed in acute lymphoblastic leukemia (ALL) and is currently in Phase I. The trials for UCART19 are sponsored by Servier. The current approach with UCART19 is based on the preliminary positive results from clinical trials using autologous products based on the CAR technology. UCART19 has the potential to overcome the limitation of the current autologous approach by providing an allogeneic, frozen, “off-the-shelf” T cell based medicinal product.

In November 2015, Servier acquired the exclusive rights to UCART19 from Cellectis. Following further agreements, Servier and Allogene Therapeutics began collaborating on a joint clinical development program for this cancer immunotherapy product. Allogene Therapeutics has been granted exclusive rights by Servier to UCART19 in the United States, while Servier retains exclusive rights for all other countries.

 

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,700 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

 

Press contacts:

Sonia MARQUES         : media@servier.com – Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
Karine BOUSSEAU       : media@servier.com – Tel. +33 (0)1 55 72 60 37 / + 33 (0) 6 49 92 16 05

 

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.

 

AlloCAR T™ cell therapies are engineered from cells of healthy donors, which is intended to allow for creation of inventory for on demand use in patients. This approach is designed to eliminate the need to create personalized therapy from a patient’s own cells, simplify manufacturing, and reduce the time patients must wait for CAR T cell treatment. The Allogene portfolio includes rights to 16 pre-clinical CAR T cell therapy targets and UCART19, an AlloCAR T™ therapy candidate currently in Phase 1 sponsored by Servier for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).

 

For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

 

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the progress and success of the UCART19 clinical program. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form S-1 originally filed with the SEC on September 14, 2018. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

 

Allogene Media/Investor Contact:

Christine Cassiano

Chief Communications Officer

(714) 552-0326

Christine.Cassiano@allogene.com